Reply  by Bursi, Francesca et al.
g
u
t
t
p
m
R
83JACC Vol. 60, No. 1, 2012 Correspondence
July 3, 2012:80–46. Tay SK, Jenkins D, Maddox P, Hogg N, Singer A. Tissue macrophage
response in human papillomavirus infection and cervical intraepithelial
neoplasia. Br J Obstetr Gynaecol 1987;94:1094–7.
7. al-Saleh W, Delvenne P, Arrese JE, Nikkels AF, Pierard GE, Boniver
J. Inverse modulation of intraepithelial Langerhans’ cells and stromal
macrophage/dendrocyte populations in human papillomavirus-
associated squamous intraepithelial lesions of the cervix. Virch Arch
1995;427:41–8.
8. Bonnez W, Reichman RC, Strussenberg J, Roberts NJ Jr. In vitro
interactions between bovine papillomavirus and human monocytes and
macrophages. Intervirology 1991;32:246–52.
9. van Vlijmen B, Gerritsen G, Franken A, et al. Macrophage p53
deficiency leads to enhanced atherosclerosis in APOE*3-Leiden trans-
genic mice. Circ Res 2001;88:780–6.
10. Merched AJ, Williams E, Chan L. Macrophage-specific p53 expres-
sion plays a crucial role in atherosclerosis development and plaque
remodeling. Arterioscler Thromb Vasc Biol 2003;23:1608–14.
Echocardiographic Evaluation
of Pulmonary Artery Pressure
in Patients With Heart Failure
We read with great interest the report by Bursi et al. (1) on the
prognostic value of pulmonary pressure in heart failure (HF).
The investigators used Doppler-determined pulmonary artery
systolic pressure (PASP), which requires an estimation of right
atrial pressure by the diameter and respiratory variation of the
inferior vena cava. This approach was initially followed to
provide values comparable with those of right-heart catheter-
ization. However, the almost arbitrary estimation of right atrial
pressure and the use of reference values for PASP derived by
right-heart catheterization worsen the reproducibility and reli-
ability of Doppler measurements. We first identified this
problem 15 years ago while studying pulmonary hypertension in
beta-thalassemia, and we proposed the use of tricuspid regur-
gitant velocity and peak systolic tricuspid pressure gradient
alone (2). To determine a reference range for tricuspid pressure
radient, we studied a group of healthy subjects and found an
pper normal limit of 30 mm Hg, which corresponds to a
ricuspid regurgitant velocity of 2.7 m/s (3). At present,
ricuspid regurgitant velocity, with a threshold of 2.7 m/s, is the
roposed method for the echocardiographic screening of pul-
onary hypertension (3).
A tricky aspect in the echocardiographic evaluation of PASP
in HF is the loading conditions at the time of examination (4).
Patients with acute HF and lung congestion would have
considerably high PASP reflecting the acutely increased left
ventricular filling pressures, not the true, steady-state passive
and active component of pulmonary hypertension. This param-
eter should be taken under consideration while evaluating
patients with acute HF, and the examination should be repeated
after clinical stabilization. Furthermore, it should be stressed
that ejection fraction is a rough estimate of systolic left
ventricular function, and this may account for the lack of
association between PASP and systolic dysfunction severity
observed by Bursi et al. (1).
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Reply
We thank Drs. Farmakis and Aessopos for the opportunity to
clarify important aspects of the prognostic use of pulmonary artery
systolic pressure (PASP) measured by Doppler in patients with
heart failure (1). Although Doppler is the preferred tool to measure
pulmonary pressures in practice (2), we agree that the estimation of
right atrial pressure has limitations (3).
The upper limit of normal of 2.7 m/s corresponding to a peak
gradient of 30 mm Hg was tested in a small group of younger
(mean age 38.9  12.7 years), healthy, nonsmoking subjects (4).
Thus, it is applicable to similar, relatively young populations
such as patients with beta-thalassemia or pulmonary arterial
hypertension and when right atrial pressure is thought to be
normal (5). Hence, this cutoff is of less relevance in older
populations with greater comorbidity, as PASP increases with
age, and patients with heart failure are elderly. Because there is
no universally accepted cutoff value to define pulmonary hyper-
tension, we analyzed the entire distribution of pulmonary
pressures and analyzed PASP with tertiles or continuously,
rather than applying an arbitrary cutoff. We showed that the
higher the PASP, the worse the prognosis, and the estima-
tion of right atrial pressure has no bearing on this continuum of
risk.
We defined heart failure by epidemiological criteria, and our
goal was not to distinguish the acute increase in filling pressures
from the chronic passive or active component of pulmonary
hypertension. We demonstrated that Doppler estimation of PASP
was feasible in most patients (91%) in the community and that
when elevated, it strongly and independently predicted outcome
regardless of the mechanism of pulmonary hypertension.
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July 3, 2012:80–4Finally, although ejection fraction is an imperfect tool to
measure systolic function, it is the most validated method, is widely
available, and is recommended by all guidelines.
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